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Abstract
Oncology clinical trials provide opportunity to advance care for patients 
with cancer. Bridging basic science with bedside care, cancer clinical trials have 
brought new and updated scientific knowledge at a rapid pace. Managing subject 
data in translation science requires a sophisticated informatics infrastructure that 
will enable harmonized datasets across all areas that could influence outcomes. 
Successful translational science requires that all relevant information be made 
readily available in a digital format that can be queried in a facile manner. Through 
a translational science prism, we look at past issues in cancer clinical trials and the 
new National Institutes of Health/National Cancer Institute initiative to address the 
need of database availability at an enterprise level.
Keywords: translational science, IROC, clinical trials, radiation oncology, NCTN, 
imaging, NCTN, TCIA
1. Introduction
Translational science provides the opportunity to apply advances in science 
directly to patient care. In oncology, new and important scientific information 
is moving forward at an enterprise level. Managing data for translational science 
requires a sophisticated informatics infrastructure that can harmonize multiple 
datasets on subjects in all areas that influence outcome. Medical history, stage of 
disease, disease location, surgery, pathology genomic/proteomics imaging, radia-
tion therapy, and medical oncology are equally important in determining outcome 
both in tumor control and normal tissue function post-therapy. In this chapter, we 
describe opportunities moving forward to enhance our knowledge and application 
of science to patient care.
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2. Problems of the past
The primary mechanism for oncology clinical development over the past 50 years 
has been in the planning and execution of clinical trials. The oncology clinical trial pro-
gram in the National Cancer Institute (NCI) began as small groups of clinical investiga-
tors driven by the common need to potentially improve the care of subjects undergoing 
cancer therapy. The groups quickly grew into larger organizations of adult and pediatric 
oncologists, which included representation from all oncology disciplines in surgery, 
medical oncology, and radiation therapy. By 1980, pediatrics was recognized as its own 
discipline and the Pediatric Oncology Group (POG) was established by the merger 
of the pediatric divisions of the former Cancer and Leukemia Group B (CALGB) 
and SWOG. In 1995, imaging was recognized as its own discipline and the American 
College of Radiology Imaging Network (ACRIN) was established to meet the growing 
need of imaging acquisition and imaging science in clinical trials. Although each of the 
established groups housed radiation oncology as a discipline committee, the Radiation 
Therapy Oncology Group (RTOG) was established to promote radiation oncology as a 
discipline with a pathway to evaluate radiation technology and comprehensive radiation 
therapy. In its halcyon moment, there were 10 cooperative groups each with its own 
statistical data center and tissue bank resource center. The cooperative groups have been 
responsible for generating many of the most important publications on oncology care 
over the past 60 years and have become the model for validating progress in oncology. 
Core services in imaging and radiation therapy were established to manage specified 
needs in cooperative group clinical trial management. These included the Radiological 
Physics Center (RPC) and the Quality Assurance Review Center (QARC) as well as 
the American College of Radiology (ACR). As radiation oncology matured into an 
image-directed discipline, the radiation oncology quality assurance centers assumed a 
greater responsibility into collecting images used to develop target volumes of choice 
for radiation therapy treatment planning. In pediatrics, the images were not siloed as 
segregate entities between radiology and radiation therapy but applied symbiotically to 
all investigators for target definition and assessment of response in a single data review 
system. This enhanced the synergism between radiologists and radiation oncologists in 
the care of children [1]. In 2007, a recommendation was made by a group designed to 
review and assess the cooperative group mechanism and functions. The recommenda-
tion was to decrease the number of the individual cooperative groups and consolidate 
core services including tissue banks, data management centers, and process review of 
quality assurance [2]. The pediatric groups had merged into the Children’s Oncology 
Group (COG) and as the restructuring started to mature, COG was positioned to be 
one of the five funded groups. The transition was completed by 2014. SWOG (formerly 
South West Oncology Group) chose to remain a single entity. The National Surgical 
Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group 
(RTOG), and the Gynecologic Oncology Group (GOG) merged as an administrative 
entity now known as NRG Oncology. The Cancer and Leukemia Group B (CALGB), 
American College of Surgeons Oncology Group (ACOSOG), and the North Central 
Cancer Treatment Group (NCCTG) formed the Alliance for Clinical Trials in Oncology 
and the Eastern Cooperative Oncology Group (ECOG) merged with the American 
College of Radiology Imaging Network (ACRIN) to form the ECOG-ACRIN Cancer 
Research Group. Each of the groups maintains an operation center as well as a statistical 
and data management center with NRG having more than one center. Tissue banking 
overlaps between the groups. The image acquisition and management and radiation 
therapy quality assurance are managed by the Imaging and Radiation Oncology Core 
(IROC), which was constituted by the existing imaging and radiation therapy quality 
assurance centers. These centers include the Radiologic Physics Center (RPC), the 
Quality Assurance Review Center (QARC), the Wright Imaging Center at Ohio State, 
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and the American College of Radiology (ACR) core quality assurance centers in imag-
ing and radiation oncology [1, 3].
The integration of the cooperative groups established an economy of scale for the 
NCI clinical trials program. The five NCTN groups house a significant amount of 
data. These data include outcome data, tissue banks data, and IROC hosting invalu-
able information important for clinical trial outcome analysis. These data libraries 
house the largest volume of oncology-related information in the world. Because the 
data are acquired on clinical trials, the datasets and outcome information are the best 
in the world for consistency in data acquisition and management and completeness 
of the information. They are among the best resources in the world for performing 
outstanding translational science research and comparing institutional translational 
science against validated datasets. Currently, the data are fragmented and siloed 
within the multiple remaining statistical centers, tissue banks, and IROC. Moving 
salient trial information into a single or synergistic data system would be an impor-
tant objective promoting translational science. Hundreds of thousands of complete 
datasets are readily available in these systems, which can be used to promote indi-
vidual work and serve to validate work of translational scientists for the next genera-
tion of clinical trials. This is the goal of big data acquisition and data management of 
this information. Each subject on study has pathology, imaging, therapy, and data 
for outcome analysis. Validated datasets with consistent and uniform acquisition of 
information will permit accurate assessment of trial outcome and provide quantita-
tive significance to the work. The potential for successful application of this effort is 
within our reach, the challenge is to define a pathway to achieve the goals of the work.
Problem solving in oncology is challenging. To move the field forward with 
strong translational science and apply balanced judgments for disease manage-
ment, the information acquired for review must be robust to appropriately power 
the study question and have the quality needed to be certain that the conclusions 
are accurate and can be validated. Oncology data management can be challenging 
if the information under review is incomplete and unvalidated, resulting in inac-
curate conclusions established in outcome analysis. The database must also undergo 
self-renewal as process improvements become standard for evaluating outcome 
imaging to validate patterns of failure and pathology to review change in biomarker 
status relative to disease progression. Tools for biomarker identification, imaging, 
radiation oncology, and applied medical oncology are under constant revision and 
databases for translational science need constant maintenance to insure accuracy 
and applicability. Future strategic translational science objectives are clear and 
unambiguous. The more complete and accurate the information acquired, the more 
successful science can be applied to the bedside. In the next section, we will describe 
challenges in clinical trial outcome interpretation when information is incomplete.
3. Problems in clinical trial interpretation
3.1 Hodgkin lymphoma
Hodgkin lymphoma is a unique disease than can affect children, adolescents, and 
adults of all ages. Chemotherapy has become the initial and primary therapy for this 
disease with choice of agents and duration of therapy based on stage at presentation, 
subject medical status, and response to induction therapy. The use of radiation ther-
apy remains under continued refinement and influenced by both response to che-
motherapy and volume of tumor at presentation. Pediatric Oncology Group protocol 
8725 evaluated what would be today called intermediate and advanced stage subjects. 
In this study, subjects were treated with eight cycles of hybrid chemotherapy 
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(ABVD-MOPP). After completion of chemotherapy, subjects were randomized to 
observation or to receive radiation therapy to all sites of disease identified on imaging 
at presentation. In the original Journal of Clinical Oncology publication, there was no 
difference in outcome in subjects who received radiation therapy [4]. Retrospective 
analysis of the study required imaging at presentation and before radiation therapy. 
The results revealed that subjects who received study-compliant radiation therapy 
had a survival rate that was 10% superior to those who received chemotherapy only. 
For the subjects treated in a manner not compliant to study guidelines (deviation), 
the survival was identical to those who received chemotherapy alone. In other words, 
subject outcome with chemotherapy was not improved using consolidation radio-
therapy in a non-study-compliant manner. Most study deviations were secondary to 
excluding original disease from the treatment field [4, 5].
Because of the study deviation rate, the next series of clinical trials in Hodgkin 
lymphoma required that the radiation therapy fields be reviewed pre-radiation 
therapy at the Quality Assurance Review Center (QARC/now IROC). The trials 
evaluated early stage subjects with therapy titration secondary to response after two 
cycles of chemotherapy and subjects with intermediate risk disease. With pre-
treatment review of radiation therapy objects, compliance to study was outstand-
ing. However, the images at presentation and response were collected by QARC to 
(1) confirm response and (2) define radiation therapy treatment fields. The images 
were reviewed retrospectively for response confirmation and the central review 
agreed only 50% of the time with the site assessment, demonstrating the need to 
define response in a consistent manner if clinical trials were going to be designed to 
either titrate or augment therapy based on response to treatment [6].
COG AHOD0031 was the first clinical trial in the world to use central review 
of imaging objects to assess response to treatment and to review radiation therapy 
treatment objects in real time. The real time review of objects was imbedded into 
the trial design structure. The image review and the review of radiation therapy 
treatment objects were completed at QARC with immediate feedback to site and 
COG statistical center, which in turn triggered both secondary and tertiary points 
of randomization with therapy titration based on good to complete response and 
therapy augmentation if response was incomplete (Figure 1). The trial accrued 
more than 1700 subjects. The completeness of the database, including outcome 
images, have generated many secondary projects including response in bone 
with PET, radiomics of response to chemotherapy in pulmonary parenchyma and 
pleural effusions, and patterns of failure on protocol therapy [8–10]. The data 
management process involved in COG trials has established the infrastructure for 
translational science. Pathology objects are housed in tissue banks and outcome 
information is housed at the statistical center; nevertheless, this information 
could be made available as needed for secondary projects to be completed. One 
of the goals moving forward is to have all this information available in a single 
format. This will be discussed in greater length in The Cancer Imaging Archive 
(TCIA) section.
The advantage to the data management system housed at IROC for COG is 
the current ability to now manage clinical trials for many subsets of subjects with 
Hodgkin lymphoma in a nimble manner with international involvement. With 
digital data transfer tools, information can be reviewed in real time to effectively 
manage adaptive trials in a facile manner. Very young subjects, older subjects with 
medical co-morbidities, CD30 therapies, and immunotherapy are now under study 
with real-time review of response coupled with biomarker analysis [11]. Expanding 
this strategy to a global and quantitative function is how translational science can 
be applied on an enterprise basis. Creating a central resource of all cancer research 
information and objects for investigators would enhance next generation science.
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3.2 Breast
Clinical trials have been the infrastructure to process improvements in care for 
breast cancer patients. The NSABP (National Surgical Adjuvant Breast and Bowel 
Project) clinical trial B-06 confirmed the use of radiation therapy in the definitive 
management of breast cancer. Clinical trials have optimized chemotherapy in this 
disease, conformed the utility of hormonal therapy, and provided us the platform to 
titrate therapies including surgery. The advantages of clinical trials in breast cancer 
are self-evident [12, 13]. Likewise, clinical trials in breast cancer also reflect the 
problems associated with limited data acquisition and how unintentional omission 
of data acquisition negatively influences translational science.
The former CALGB conducted a series of well-designed clinical trials intended 
to evaluate the role of chemotherapy dose escalation with Adriamycin and Cytoxan 
with the sequential additional of Taxol in node positive subjects [13]. These trials 
performed in sequence predated the routine use of Her-2-Neu-directed therapy in 
this disease. Likewise, these trials in development predated the confirmation that 
radiation therapy provided a survival advantage for node positive breast cancer sub-
jects treated with chemotherapy. The decision was made by the principal investiga-
tor not to either collect or inquire how local care to the breast and lymph nodes was 
applied and accomplished. The decision was made in this direction because there 
was no unambiguous information available at the time of trial development that 
local care or local control affected survival; therefore, the utility of data collection 
was not thought to be of consequence and did not merit the cost or effort. Evidence 
to the contrary was made public in 1997 when two separate clinical trials were 
published together, both demonstrating a survival advantage when node positive 
subjects were treated with radiation therapy on an adjuvant basis [14, 15]. This made 
clinical trial interpretation challenging because subject outcome relative to type, 
duration, and specific chemotherapy could not be solely assigned to the chemother-
apy delivered. Many of the subjects on these series of studies also received radiation 
therapy to dose and volumes that were non-uniform and site/investigator specific.
To attempt and address this situation, Sartor and colleagues from QARC (now 
IROC Rhode Island) attempted to collect radiation therapy treatment information 
in a retrospective manner by contacting institutions about specific subjects. This 
Figure 1. 
Real-time imaging and radiation therapy object reviews on AHOD0031. This image is under the creative 
commons attribution license [7].
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was partially effective, however limited in execution because of several reasons. 
This effort was not the intention or part of the data management of the studies; 
therefore, site investigator enthusiasm to support the effect was non-uniform. The 
second issue was one that is now more visible in more modern clinical trials as to 
collect this information, institutional review boards (IRB) began to insist that sub-
jects on study be re-consented for this effort. Accordingly, this became a significant 
barrier to project completion [16].
These trials accrued more than 3000 subjects and were well powered to achieve 
the objectives of the study. However, only less than one-third of the radiation 
therapy information could be collected and often the information received was 
incomplete. The information received clearly indicated that without protocol 
guidelines, dose and volumes treated were significantly heterogeneous and when 
treated, subjects received therapy that was non-uniform relative to dose and volume 
and conclusions would have been difficult to validate. There was a trend for subjects 
who received Taxol to also have received radiation therapy, imposing a question as 
to which therapy, or both, provided a care advantage.
A second issue foreshadowed a problem now seen in current breast cancer clini-
cal trials. There were more than 300 local and or local regional failures in this study. 
If radiation therapy objects were collected and detailed information concerning the 
location and nature of the local failure, the application of the radiation oncology 
treatment fields, technique, and dose could be reviewed to better ascertain how 
radiation therapy can/should be applied along the chest wall and regional draining 
lymph nodes. The lack of information has led to a paralysis in our understanding of 
issues than remain today.
ACOSOG Z0011 (Z11) was a clinical trial designed to evaluate limited axillary 
surgery in subjects with breast cancer including those with limited nodal involve-
ment. The objective was to validate that sentinel lymph node staging coupled with 
radiation therapy would be non-inferior to more comprehensive axillary surgery 
[17]. The trial asked for what is referred to as “tangential radiation therapy.” This 
would imply that the axillary volume was treated to a partial volume. In stud-
ies evaluating this point using anatomical guidelines superimposed on radiation 
therapy treatment fields, approximately 60% of the axilla would be included in a 
traditional field that would not extend superiorly to the axillary vein nor posteriorly 
to the latissimus muscle [18]. The study proved to be positive relative to limited 
axillary surgery. However, radiation therapy treatment objects were not collected as 
part of the study, giving the impression that partial volume RT to the axilla could be 
considered a new standard of care. Jolie and colleagues decided to review this point 
and with several colleagues including support from QARC (IROC), attempts were 
made to gather specific information as to how radiation therapy was delivered to 
subjects on study. The investigators encountered similar barriers to data acquisition 
relative to site enthusiasm and IRB approval. However, the investigators were able 
to determine that a significant number of subjects were treated with more com-
prehensive radiation therapy to extended volumes including regional lymph nodes 
that were not study directed. Therefore, conclusions concerning the application of 
radiation therapy to limited volumes of the axilla are premature [19].
If radiation therapy digital datasets and radiation dose were collected as part of 
the study, it is possible that interventional review pre-therapy could have been per-
formed and the data set could have been more uniform. In this situation, outcome 
images could be applied to patterns of failure analysis and define outcome relative 
to axillary therapy with more security. This issue continues to haunt even the most 
current breast cancer trial attempting to discern the appropriate radiation therapy 
target volume in subjects with limited and more extended axillary surgery. This has 
influence in normal tissue outcome and despite nearly 50 years of clinical trials, it 
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remains unanswered. If the datasets were complete, it is possible we might be closer 
to understanding how to apply therapy for both tumor control and optimal normal 
tissue function. This is of increasing importance as radiation therapy is now being 
asked to treat nodal regions with more limited surgery. If information acquired on 
study was more complete, we may be further along in our understanding of field 
placement. This also limits our ability to perform translational science including 
pathology biomarkers for local failure and other potential areas of interest to the 
oncology community. These are problems of omission of data acquisition and 
limit our ability to use these datasets to review information in retrospect and apply 
knowledge to the next generation of clinical trials.
3.3 Head/neck
There is much to be learned as issues of head and neck management are influ-
enced by biomarkers and relationship to viral origin of disease. To be accurate in 
data assessment, pathology and imaging objects need to be complete to intercom-
pare both staging and therapy execution/outcome. Non-uniform treatment execu-
tion can limit study success and utility of the dataset for translational science.
Tirapazamine gained prominence as a hypoxic cell sensitizer to radiation ther-
apy with favorable phase 2 results. In the HeadSTART clinical trial, Tirapazamine 
was randomized with traditional chemoradiotherapy for locally advanced squa-
mous cell carcinoma of the head/neck. In this study, both imaging and radiation 
therapy quality assurance objects underwent on treatment review at QARC for 
study compliance. Pre-treatment review was not utilized because the trial included 
many international partners and most of the involved sites credentialed for partici-
pation had primitive digital transfer tools at the time of clinical trial participation. 
The trial management committee determined that pre-therapy review would 
potentially be a barrier to accrual. Nearly 25% of the cases required radiation field 
adjustments to ensure that full dose was received to gross tumor as seen on central 
review. Of the 211 requests for field alteration, 116 chose not to adjust the fields and 
95 chose to make the adjustment. In all cases, the potential for deviation was due to 
potential exclusion of gross tumor from full dose and protocol-compliant radia-
tion. If the adjustment was made on treatment, subjects had reasonable survival; 
however, their survival was less than those who had a compliant plan de novo. If 
adjustments were not made, except for two cases, the trial management committee 
agreed with the assessment of the on-treatment reviewer. The trial committee asked 
the primary on-treatment reviewer to score all study deviations into two categories, 
clinically meaningful or not. Clinically meaningful deviations excluded gross tumor 
from full-dose radiation therapy. Subjects with clinically meaningful deviations had 
a significant decrease in survival while those whose deviations were not considered 
significant had an outcome identical to those whose plans were adjusted for compli-
ance on treatment. Both groups had survival less than the subjects who had a com-
pliant plan upfront. The most unfortunate aspect of this study is the deviation rate 
on trial over rode the point of randomization on the study, rendering the experi-
mental arm uncertain, secondary to quality of the radiation therapy. Therefore, the 
cases become less helpful for translational science endeavors including pattern of 
failure analysis as the outcome was influenced by the quality of the data [20, 21].
Current studies in head and neck cancer place emphasis on the role of immu-
notherapy in both comparing the traditional platinum-based therapy coupled 
with non-inferiority objectives to evaluate toxicity. In these trials, investigators 
have matured in the coverage of gross tumor. However, there is new disparity on 
coverage of targets deemed of intermediate and low risk as investigators are empiri-
cally titrating volume treated to ameliorate mucosal discomfort and late effects 
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to multiple normal tissue volumes. Therapeutic titration will influence toxicity 
profiles. If investigators are titrating volumes, modern protocols may unfairly favor 
toxicity profiles generated by new regimens in comparison to historical standard. 
Complete datasets including outcome imaging with patterns of failure will be 
important to compare both tumor control and toxicity moving forward.
These are important datasets as strategies in artificial intelligence and machine 
learning in radiology and radiation oncology need to be developed from accurate 
and complete datasets, especially as the origin of disease becomes multifactorial in 
origin. If objects are not targeted correctly or per protocol, it will be impossible to 
develop accurate artificial intelligence (AI) machine tools that can be applied for 
translational science moving forward.
3.4 Lung
Treatment of patients with lung malignancy is challenging as metrics for normal 
tissue function extend beyond the anatomical constraints that can be defined in 
radiation oncology planning images. Both tumor control and normal tissue func-
tion are influenced by dose to target and radiation dose to normal tissue, including 
volumes of parenchyma receiving low, intermediate, and high doses. One of the 
challenges moving forward is to ensure that volumes are drawn accurately to assess 
tumor control and cardio-pulmonary function. RTOG 0617 study evaluated the 
role of targeted therapy coupled with both low- and high-dose radiation therapy to 
tumor target. Radiation therapy treatment objects were submitted for review with-
out diagnostic images to validate that what was drawn for treatment reflected all the 
tumor anatomy. It was assumed, perhaps accurately, that the planning CT would be 
sufficient to confirm that all disease was included in the intended target. Although 
the study did not show a benefit to high-dose radiation, the paradox was that in the 
early phase of the trial, the higher dose arm had statistically worse local control. 
One explanation is that gross tumor may not have been fully contoured in selected 
cases and possibly influenced trial outcome. As such, without primary imaging and 
outcome imaging, it is difficult to confirm the pattern of failure, possibly render-
ing these datasets less useful for secondary analysis. Complete datasets would be 
helpful to validate trial outcome and increase the utility of the data for secondary 
analysis and translational science [22].
4. Analysis
Successful translational science requires that all relevant information be made 
readily available in an informatics format that can be queried in a facile manner. 
Incomplete datasets can lead to conclusions that may be inaccurate. Complete 
datasets will permit the facts to drive study outcome and investigators will feel the 
analysis is accurate. A senior clinical trial investigator once stated that the time to 
write your protocol is when you analyze your data as you finally begin to see the 
questions you should have both asked and anticipated in the design phase of the 
trial. This is why informatics platforms must have enterprise-level query function to 
help answer questions not anticipated in study design. Datasets from clinical trials 
potentially make the best tools for moving translational science forward as the (1) 
subjects are entered on trial for a specific purpose, (2) the stage and appropriateness 
for subject entry are confirmed with uniform standards, (3) information includ-
ing pathology and imaging are collected and collated in a uniform manner, (4) 
subjects are treated in a uniform manner with treatment data available for review, 
and (5) outcome information is available including imaging to validate outcome as 
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appropriate. These datasets permit evaluation of a potential new biomarker as (1) 
the information may be available in situ as a digital object and (2) additional tissue 
may be available as part of an exhaustible resource housed in a tissue bank. Nimble 
query function can permit intercomparison between subjects on the same trial or 
other subjects on different studies with similar demographics for analysis. This 
can potentially evaluate and compare those with similar biomarkers on different 
studies. The datasets become a rich resource for science. At the moment within both 
industry and the NCTN, the information is housed in disparate locations including 
statistical data centers that house subject demographics and outcome, IROC which 
houses images and radiation therapy treatment objects, and tissue banks which 
house both digital maps of known biomarkers and tissue help for additional studies 
when needed. As a result, efforts to perform secondary analysis on objects become 
challenging and often lost in process and sequential approvals for use. This can take 
considerable time and effort and often the scientific question is muted and defeated 
by processes designed for data protection.
To make science move forward at an enterprise level, this information needs 
to be housed in in a single platform designed to promote and support the modern 
scientist with nimble and comprehensive query function for robust data review. 
The next section will discuss how these objects are currently managed and present a 
strategy for modern science moving forward.
5. The cancer imaging archive (TCIA)
TCIA is an initiative of the National Institute of Health (NIH) and the National 
Cancer Institute (NCI) to address the need for enterprise database availability to 
promote translational science and to validate concepts and ideas against a strong 
database. The archive resides in the public domain and the objects are fully de-iden-
tified per government standards. The principal investigator of TCIA is Fred Prior, 
PhD, who is the chair of quantitative science at the University of Arkansas. Dr. Prior 
has long-standing expertise in database management and development of image 
datasets. He has applied his expertise to this effort coupled with co-investigators 
Joel Saltz, MD, PhD, and Ashish Sharma, PhD. Dr. Saltz is the chair of bioinformat-
ics at Stony Brook University and an international expert in digital pathology and 
integrated database function. Dr. Sharma is at Emory University and is an informat-
ics expert who helps move TCIA to enterprise function.
The digital archive houses imaging and outcome information that can be used 
for translational science. The current portfolio includes datasets from all cancer 
subtypes in adult oncology and will soon be updated with datasets from pediatric 
oncology. The information includes clinical information, imaging, radiation 
therapy datasets and treatment plans, pathology objects including genomics, and 
other supplemental information required for analysis. The current portfolio can 
be accessed through www.thecancerimagingarchive.net. TCIA is an important 
initiative as it makes information available to all interested scientists who can apply 
information directly to their projects of interest.
As TCIA moves forward, it will be essential to find mechanisms for enterprise-
level data capture and uniform data formatting for all trials both within the NCTN 
and industry. Clinical trials within the NCTN will likely need to be designed in the 
future with data capture as part of the protocol and processes imbedded in the trial 
will need to be made uniform in the trial design to be uploaded to TCIA once the 
trial is complete and objects fully de-identified for the public archive. Investigators 
will want to be able to look at specific subjects’ subsets in clinical trials and evaluate 
both image and biomarker expression for subsets both within individual trials and 
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intercompare with other trials for outcome analysis. This will be true in all adult 
and pediatric oncology subtypes. We are learning more each day about response-
directed therapies and the relationship of response and disease progression relative 
to biomarkers. The informatics tools will need to be robust to accommodate this ele-
ment of data exchange and evaluation. Digital pathology will play an increasingly 
important role including capture of profiles that are identified to date in a manner 
similar to oncotype for breast cancer. Tissue will need to be stored for the biomarker 
not yet identified. Digital capture makes identified objects inexhaustible while 
tissue is exhaustible, hence the reason we need to store and protect this invaluable 
resource. Radiation therapy treatment plans will need to be fused with images 
that define targets and correlate to images that review the pattern of failure. It will 
be through these mechanisms we will all mature in our understanding of disease 
processes and the success/failure of our applied therapies [23, 24].
6. Conclusions
Enterprise-level function of comprehensive clinical trial datasets is closer to 
reality than it has been in the past. The quality of the dataset will significantly influ-
ence the quality of our understanding of the applied information and how we use 
clinical information moving forward. Efforts need to be made to optimize existing 
datasets in the NCTN and industry to help move knowledge forward in a manner 
we can validate and trust.
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